

# Resource Summary Report

Generated by [NIF](#) on Aug 20, 2026

## Human M-CSF R/CD115 Antibody

RRID:AB\_2085247

Type: Antibody

### Proper Citation

R and D Systems Cat# MAB3292, RRID:AB\_2085247

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2085247](http://antibodyregistry.org/AB_2085247)

**Proper Citation:** R and D Systems Cat# MAB3292, RRID:AB\_2085247

**Target Antigen:** M-CSFR/CD115

**Host Organism:** Mouse

**Clonality:** monoclonal

**Comments:** Applications: ELISA Capture (Matched Antibody Pair)

**Antibody Name:** Human M-CSF R/CD115 Antibody

**Description:** This monoclonal targets M-CSFR/CD115

**Target Organism:** human

**Clone ID:** 61715

**Antibody ID:** AB\_2085247

**Vendor:** R and D Systems

**Catalog Number:** MAB3292

**Alternative Catalog Numbers:** MAB3292-100, MAB3292-SP, MAB3292-500

**Record Creation Time:** 20250820T012606+0000

**Record Last Update:** 20250820T105517+0000

### Ratings and Alerts

No rating or validation information has been found for Human M-CSF R/CD115 Antibody.

No alerts have been found for Human M-CSF R/CD115 Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Smith BD, et al. (2021) Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Molecular cancer therapeutics, 20(11), 2098.

Smith BD, et al. (2019) Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer cell, 35(5), 738.